CN116531337A - 一种莫西菌素缓释微球及其制备方法和应用 - Google Patents
一种莫西菌素缓释微球及其制备方法和应用 Download PDFInfo
- Publication number
- CN116531337A CN116531337A CN202310427289.4A CN202310427289A CN116531337A CN 116531337 A CN116531337 A CN 116531337A CN 202310427289 A CN202310427289 A CN 202310427289A CN 116531337 A CN116531337 A CN 116531337A
- Authority
- CN
- China
- Prior art keywords
- moxidectin
- molecular weight
- plga
- release microsphere
- microspheres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 87
- 229960004816 moxidectin Drugs 0.000 title claims abstract description 62
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000012074 organic phase Substances 0.000 claims abstract description 22
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 15
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000004945 emulsification Methods 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000010008 shearing Methods 0.000 claims abstract description 10
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 9
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 9
- 239000008367 deionised water Substances 0.000 claims abstract description 9
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 9
- 239000000839 emulsion Substances 0.000 claims abstract description 7
- 239000012071 phase Substances 0.000 claims abstract description 7
- 238000004108 freeze drying Methods 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 238000004140 cleaning Methods 0.000 claims abstract description 3
- 238000007865 diluting Methods 0.000 claims abstract description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract 20
- 238000000034 method Methods 0.000 claims description 18
- 238000013268 sustained release Methods 0.000 claims description 15
- 239000012730 sustained-release form Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 10
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical group CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 24
- 229940079593 drug Drugs 0.000 abstract description 22
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 7
- 241000282326 Felis catus Species 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 208000030852 Parasitic disease Diseases 0.000 abstract description 4
- 239000000273 veterinary drug Substances 0.000 abstract description 3
- 239000002245 particle Substances 0.000 description 12
- 238000011068 loading method Methods 0.000 description 10
- 238000005538 encapsulation Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000005660 Abamectin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000777206 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 40 Proteins 0.000 description 1
- 102100031284 Ubiquitin carboxyl-terminal hydrolase 40 Human genes 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- -1 moxidectin lipid Chemical class 0.000 description 1
- 231100001081 no carcinogenicity Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000004540 pour-on Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及兽药制备技术领域,具体涉及一种莫西菌素缓释微球的制备方法,包括如下步骤:将莫西菌素与PLGA重量比为1:1~4的混合物溶于二氯甲烷中,并加入0.1%~2.0%的抗氧化剂溶解形成有机相;将有机相迅速倒入至水相(1%的聚乙烯醇PVA溶液)中,高速剪切乳化,得到O/W乳液,将O/W乳液用4倍体积的去离子水稀释,常压300rpm搅拌4h挥去有机溶剂固化形成微球;将微球用去离子水反复清洗除去多余的PVA,收集微球,冷冻干燥即得莫西菌素缓释微球。本发明通过将不同分子量的PLGA以一定的比例混合,显著改善了微球的迟滞期。该制备技术操作简单,获得微球释药周期长、安全性高、依从性强;能够长期有效防治犬猫体内外寄生虫病。
Description
技术领域
本发明涉及兽药制备技术领域,具体涉及一种莫西菌素缓释微球及其制备方法和应用。
背景技术
寄生虫病是犬猫常见的疾病之一,具有体内外寄生虫种类繁多、患病不受宠物年龄、种类及健康程度等因素的影响、传染性强、防控困难的特点,各种体内外寄生虫会不同程度地通过夺取动物营养,损害动物组织细胞并分泌毒素,严重危害宠物健康及公共卫生安全。
莫西菌素又名莫昔克丁、莫西克汀、莫西丁克,是新一代大环内酯类抗寄生虫药物,如图1所示。与其他阿维菌素类药物相比,其成分单一,驱虫谱广,半衰期长,安全性更高,在极低剂量下就有很强的抗体内外寄生虫活性,特别是对犬的安全性显著高于伊维菌素等药物。目前,临床上常用的剂型包括浇泼剂、注射剂、滴剂、胶丸、微球和缓释巨丸等。
微球(microspheres)是指药物溶解或分散在高分子材料基质中形成的微小球状实体,属于基质型骨架微粒。通过微球内部的孔道扩散及高分子材料自身的溶蚀降解等方式,使药物在一定时间内以恒定速率释放到环境中,来控制药物在体内外的释放行为,达到缓慢释放的效果。聚乳酸/羟基乙酸共聚物(PLGA)具有无毒、无刺激、无致癌性、生物可降解、生物相容性高等优点,在缓控释或定向给药系统领域中应用极为广泛。目前PLGA微球长效递药系统已成为兽药研发的热点之一。该递药系统不仅可以延长药物释放时间、减小给药次数、提高宠物顺应性、而且可以降低药物毒副作用,减小宠物主人的经济负担。
目前,莫西菌素现有制剂主要为一月给药一次的滴剂浇泼剂等普通制剂,需要每月给药一次,若忘记给药可能会将宠物暴露于被感染的危险之中。已上市的长效制剂只有硕腾(Zoetis)研发的6和/>12,但该脂质微球制剂由于安全性问题曾撤出过市场。CN 114848598 A提出使用聚乳酸和石墨烯为材料制备莫西菌素微球,但并未阐述获得微球的缓释效果;CN 111386112 A提出了一种含莫西菌素的组合物;梅里亚公司结合喷雾干燥法和热熔挤出法制备了一种莫西菌素PLGA植入剂;CN 111346046 A提出了一种莫西菌素缓释凝胶制剂;CN 110381924A提出采用微射流技术制备了粒径为80-130μm的聚合物微球制剂;US 6340671 B1提出采用喷雾干燥法制备莫西菌素脂质微球。综上,现有制剂的主要问题是缺乏有效性、安全性及长效性。因此,迫切需要开发一种安全、稳定、长效的莫西菌素长效制剂用于犬猫等宠物的体内外寄生虫的防治。
发明内容
本发明的目的在于针对背景技术中分析和存在的问题,提供一种莫西菌素缓释微球及其制备方法和应用,采用高低分子量PLGA共混的方式利用O/W乳化溶剂挥发法制备莫西菌素缓释微球长效注射剂,显著改善了微球的迟滞期,获得微球体内可以缓释至少长达2个月以上,可用于长期防治犬猫体内外寄生虫病。
为实现上述目的,本发明采用的技术方案是:
一种莫西菌素缓释微球的制备方法,其特征在于,包括如下步骤:
步骤1:将莫西菌素与PLGA重量比为1:1~4的混合物溶于二氯甲烷中,并加入0.1%~2.0%的抗氧化剂溶解形成有机相;
步骤2:将步骤1中有机相迅速倒入至水相(1%的聚乙烯醇PVA溶液)中,高速剪切乳化,得到O/W乳液,将O/W乳液用4倍体积的去离子水稀释,常压300rpm搅拌4h挥去有机溶剂固化形成微球;
步骤3:将步骤2所得微球用去离子水反复清洗除去多余的PVA,收集微球,冷冻干燥即得莫西菌素缓释微球。
优选的,在步骤1中,所述PLGA由高低分子量混合制备,其中,高分子量PLGA为LA:GA比例为75:25,分子量为50~100kDa;低分子量PLGA为LA:GA比例为50:50,分子量为5~30kDa;高低分子量PLGA重量比为1:0~1。
具体的,所述高分子量PLGA的分子量为60~80kDa;所述低分子量PLGA的分子量为10~25kDa;所述高低分子量PLGA重量比为1:0~0.1。更具体的,所述高分子量PLGA的分子量为75kDa;所述低分子量PLGA的分子量为23kDa;所述高低分子量PLGA重量比为1:0.333。
优选的,在步骤1中,所述的莫西菌素与PLGA的投料重量比为1:1~2;所述有机相中PLGA浓度为50~250mg/ml;所述有机相中抗氧化剂为二丁基羟基甲苯或丁基羟基茴香醚,重量百分比为0.1%~2.0%。
具体的,所述的莫西菌素与PLGA的投料重量比为为1:1.5;所述有机相中PLGA浓度为100~200mg/ml;所述有机相中抗氧化剂的重量百分比为0.2%~1.5%。更具体的,所述有机相中PLGA浓度为150mg/ml;所述有机相中抗氧化剂的重量百分比为1.0%。
优选的,在步骤2中,所述有机相与水相(1%PVA)的体积比为1:10~50;所述剪切乳化的速度为2000~6000rpm,所述剪切乳化的时间为1~3min。
具体的,所述有机相与水相(1%PVA)的体积比为1:20;所述剪切乳化的速度为3000~5000rpm,所述剪切乳化的时间为1.5~2.5min。更具体的,所述剪切乳化的速度为4000rpm,所述剪切乳化的时间为2min。
按照以上制备放法获得的莫西菌素缓释微球,表面成不规则多边形褶皱,粒径分布均匀在20~100μm之间,微球载药量大于30%,包封率大于85%;动物试验结果表明,该制剂体内突释小、血药浓度波动较小、体内可以缓释至少长达2个月以上。该制剂可用于长期防治犬猫体内外寄生虫。
本发明具有以下有益效果:本发明通过将不同分子量的PLGA以一定的比例混合,显著改善了微球的迟滞期。该制备技术操作简单,获得微球释药周期长、安全性高、依从性强;能够长期有效防治犬猫体内外寄生虫病。
附图说明
图1为本发明实施例中莫西菌素分子结构示意图;
图2为本发明实施例中莫西菌素缓释微球扫描电镜结果;
图3为本发明实施例中莫西菌素缓释微球粒径测定结果;
图4为本发明实施例中莫西菌素缓释微球体外释放曲线;
图5为本发明实施例中莫西菌素溶液剂组药时曲线;
图6为本发明实施例中莫西菌素缓释微球组药时曲线。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合具体实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅用以解释本发明,并不用于限定本发明。
应当理解,对本发明中提及但并没有详细说明的方法、步骤、装置、仪器、材料等,普通技术人员可以采用本领域中熟知的相应方法、步骤、装置、仪器、材料等,或按照本领域的常规知识和技术获得。
实施例1莫西菌素缓释微球的制备:称取900mg PLGA(75/25,75kDa),600mg莫西菌素,60mg BHT溶于6mL二氯甲烷中形成有机相。将有机相迅速倒入至120mL的1%PVA溶液中,4000rpm高速剪切2min形成o/w乳液。用480ml去离子水稀释后,300rpm常压搅拌4小时挥去有机溶剂固化微球。用去离子水洗涤多次出去PVA后,收集微球,冷冻干燥即得。
实施例2-4除了PLGA加入不同外,其他制备条件同实施例1。具体处方条件如下:
表1实施例2-4处方
实施例5-6除了抗氧剂加入不同外,其他制备条件同实施例1。
表2实施例5-6处方
实施例7微球粒径、形态、载药量及包封率的测定
取少量微球冻干粉,混悬于去离子水中,使用Mastersizer 2000激光粒度仪(Malvern,Worcestershire,UK)测定微球粒径。
取少量微球冻干粉至导电胶上,喷金90s,使用扫描电镜观察微球表观形态(TESCAN LYRA3 FIB-SEM,TESCAN,Brno,CR)。
精密称取20mg微球溶解于10ml乙腈中,过0.45μm有机膜,按照USP40测定莫西菌素含量,按照如下公式计算莫西菌素载药量和包封率。
载药量(%)=微球中莫西菌素的重量/总微球重量×100
包封率(%)=实际微球载药量/理论微球载药量×100
试验测得微球粒径、载药量及包封率结果如下表:
表3实施例1-4粒径、载药量及包封率试验结果
由以上结果可知,处方中加入小分子量PLGA,微球载药量和包封率不变,粒径略有变小。
微球表观形态结果如图2所示,粒径分布如图3所示,试验结果可知,微球粒径分布均匀约为45μm,微球表面有直径约为1μm的均匀褶皱。
实施例8微球体外释放试验
为了考察微球的缓释性能,在满足漏槽条件的基础上本研究采用直接加入法进行微球的体外释放研究。考虑到莫西菌素对酸、热不稳定,本研究进一步优化体外释放条件,最终确定莫西菌素缓释微球常规体外释放度测定方法如下:
释放介质:10mM PBS(pH 7.4,含0.5%SDS及0.02%NaN3);
释放条件:37±1℃水浴振摇,转速为100rpm;
释放方法:精密称取微球20mg于50mL的离心管中,加入释放介质50mL,在预定的时间点3000rpm离心10min,取上清5mL过0.45μm的水膜用HPLC测定含量,并补充等体积的新鲜释放介质,一式三份,按如下公式计算累积释放量,以时间为横坐标,以累积释放百分比为纵坐标,绘制体外释放曲线。
式中:
Ct表示各时间点测得释放介质中药物浓度,mg/mL;
V0表示释放介质的总体积,mL;
V表示每次取样的体积,mL;
W表示投入的微球总重量,mg;
X表示微球的载药量,(%)。
微球体外释放结果如图4所示,试验结果可知,微球体外可以缓释长达6个月,小分子量PLGA的加入显著缩短了微球的迟滞期。
实施例9药代动力学研究
对实施例1-4的处方进行药代动力学试验,取雄性体重为200-220g的SD大鼠30只,分为5组,第1-4组大鼠颈部皮下注射莫西菌素缓释微球1mg/kg。第五组大鼠颈部皮下注射莫西菌素溶液剂1mg/kg。具体溶液剂制备方法为:将莫西菌素40mg超声溶解于100ml 1%的Tween 80溶液中。注射前将微球混悬于水性介质中,其中水性介质包含0.87%氯化钠,0.1%Tween 80以及0.75%羧甲基纤维素钠。给药后在预定的时间点眼眶采血0.5ml,离心收集血浆,使用UPLC-MS/MS检测血浆样品中莫西菌素含量。
药代结果如图5及图6所示,药代参数如表4及表5所示。
表4莫西菌素缓释微球药代参数(mean±SD;n=6)
表5莫西菌素缓释微球药代结果比较(mean±SD;n=6)
血药浓度测定结果显示:莫西菌素缓释微球在大鼠体内可以缓释至少60天,其缓释效果显著高于溶液剂,其中实施例3在60天内的平均血药浓度可达10.72ng/ml且血药浓度波动较小,且在第30-60天血药浓度最高为8.63ng/ml。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种莫西菌素缓释微球的制备方法,其特征在于,包括如下步骤:
步骤1:将莫西菌素与PLGA重量比为1:1~4的混合物溶于二氯甲烷中,并加入0.1%~2.0%的抗氧化剂溶解形成有机相;
步骤2:将步骤1中有机相迅速倒入至水相(1%的聚乙烯醇PVA溶液)中,高速剪切乳化,得到O/W乳液,将O/W乳液用4倍体积的去离子水稀释,常压300rpm搅拌4h挥去有机溶剂固化形成微球;
步骤3:将步骤2所得微球用去离子水反复清洗除去多余的PVA,收集微球,冷冻干燥即得莫西菌素缓释微球。
2.根据权利要求1所述的一种莫西菌素缓释微球的制备方法,其特征在于:在步骤1中,所述PLGA由高低分子量混合制备,其中,高分子量PLGA为LA:GA比例为75:25,分子量为50~100kDa;低分子量PLGA为LA:GA比例为50:50,分子量为5~30kDa;高低分子量PLGA重量比为1:0~1。
3.根据权利要求2所述的一种莫西菌素缓释微球的制备方法,其特征在于:所述高分子量PLGA的分子量为60~80kDa;所述低分子量PLGA的分子量为10~25kDa;所述高低分子量PLGA重量比为1:0~0.1。
4.根据权利要求3所述的一种莫西菌素缓释微球的制备方法,其特征在于:所述高分子量PLGA的分子量为75kDa;所述低分子量PLGA的分子量为23kDa;所述高低分子量PLGA重量比为1:0.333。
5.根据权利要求1所述的一种莫西菌素缓释微球的制备方法,其特征在于:在步骤1中,所述的莫西菌素与PLGA的投料重量比为1:1~2;所述有机相中PLGA浓度为50~250mg/ml;所述有机相中抗氧化剂为二丁基羟基甲苯或丁基羟基茴香醚,重量百分比为0.1%~2.0%。
6.根据权利要求5所述的一种莫西菌素缓释微球的制备方法,其特征在于:所述有机相中PLGA浓度为150mg/ml;所述有机相中抗氧化剂的重量百分比为1.0%。
7.根据权利要求1所述的一种莫西菌素缓释微球的制备方法,其特征在于:在步骤2中,所述有机相与水相(1%PVA)的体积比为1:10~50;所述剪切乳化的速度为2000~6000rpm;所述剪切乳化的时间为1~3min。
8.根据权利要求7所述的一种莫西菌素缓释微球的制备方法,其特征在于:所述有机相与水相(1%PVA)的体积比为1:20;所述剪切乳化的速度为4000rpm;所述剪切乳化的时间为2min。
9.一种莫西菌素缓释微球,其特征在于,所述莫西菌素缓释微球采用权利要求1~8任一项所述的莫西菌素缓释微球的制备方法制备得到。
10.权利要求9所述的莫西菌素缓释微球在制备莫西菌素缓释微球注射液中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310427289.4A CN116531337A (zh) | 2023-04-20 | 2023-04-20 | 一种莫西菌素缓释微球及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310427289.4A CN116531337A (zh) | 2023-04-20 | 2023-04-20 | 一种莫西菌素缓释微球及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116531337A true CN116531337A (zh) | 2023-08-04 |
Family
ID=87453398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310427289.4A Pending CN116531337A (zh) | 2023-04-20 | 2023-04-20 | 一种莫西菌素缓释微球及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116531337A (zh) |
-
2023
- 2023-04-20 CN CN202310427289.4A patent/CN116531337A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101434334B1 (ko) | 화학 물질의 마이셀 나노입자 | |
US20100291200A1 (en) | Formulations for poorly soluble drugs | |
JP6464154B2 (ja) | S字型放出プロファイルを有するポリラクチド−ポリグリコリド微小粒子の調製 | |
SK148999A3 (en) | Gastroretentive controlled release microspheres for improved drug delivery | |
DE19819273A1 (de) | Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung | |
Brime et al. | Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration | |
US8777134B2 (en) | Suspension comprising benzimidazole carbamate and a polysorbate | |
US11344503B2 (en) | Cariprazine release formulations | |
CN102271660A (zh) | 制备持续释放微粒的方法 | |
WO2018108164A1 (zh) | 一种硼替佐米药物组合物及其应用 | |
CN101322690A (zh) | 一种稳定的药物脂质复合物 | |
WO2018108163A1 (zh) | 一种Talazoparib药物组合物及其应用 | |
CN106474070A (zh) | 一种克服停滞期、恒速释放疏水性药物的微球及制备方法 | |
CN114748428B (zh) | 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法 | |
Almeida et al. | Comparative study of sustained-release lipid microparticles and solid dispersions containing ibuprofen | |
WO2013060304A1 (zh) | 紫杉醇或其同系物的固体分散体及其制备方法 | |
JPS6163613A (ja) | 顆粒状に調整された徐放性製剤 | |
CN116531337A (zh) | 一种莫西菌素缓释微球及其制备方法和应用 | |
US20120121510A1 (en) | Localized therapy following breast cancer surgery | |
FI101855B (fi) | Menetelmä asetatsolamidia jatkuvasti vapauttavan asetatsolamidivalmist een valmistamiseksi | |
CN112156170B (zh) | 可供皮下注射的曲普瑞林缓释微球及其制备方法和用途 | |
CN101543631B (zh) | 含蜂蜡的微球基质、含有它的药物组合物及其用途 | |
Kundu et al. | Formulation and characterization of alginate microbeads of norfloxacin by ionotropic gelation | |
CN114681406A (zh) | 一种卡利拉嗪长效缓释微球及其制备方法 | |
CN115068427B (zh) | 缓释7天及缓释14天的青蒿素b微球及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |